Anicetti Vincent R 4
4 · Coherus BioSciences, Inc. · Filed Dec 9, 2020
Insider Transaction Report
Form 4
Anicetti Vincent R
Chief, Quality & Compliance
Transactions
- Sale
Common Stock
2020-12-07$18.42/sh−8,791$161,896→ 32,569 total - Exercise/Conversion
Common Stock
2020-12-07$12.37/sh+3,000$37,110→ 35,569 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-12-07−3,000→ 123,000 totalExercise: $12.37Exp: 2029-01-11→ Common Stock (3,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2020-12-07−5,791→ 0 totalExercise: $12.70Exp: 2027-08-06→ Common Stock (5,791 underlying) - Exercise/Conversion
Common Stock
2020-12-07$12.70/sh+5,791$73,546→ 41,360 total
Footnotes (4)
- [F1]Includes 31,250 restricted stock units.
- [F2]The transaction was executed in multiple trades in prices ranging from $18.30 to $18.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- [F3]The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 11, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
- [F4]All of the shares underlying this option are vested and exercisable as of the date hereof.